DNMT3A and acute myeloid leukemia: In the pre-transplant setting, there is substantial concern about using genes such as DNMT3A as MRD markers, because mutations in pre-malignant clonal proliferations are often seen at appreciable levels in otherwise successfully treated patients while AML-specific mutations in the same patient become undetectable[29,30].